Biohaven 2026: Revenue ($129.3M), Net income ($129.28M), EPS ($0.86) — 10-Q Summary
Biohaven Ltd. reported a net loss of $129.28M for 2026, with diluted loss per share of $0.86, narrowing from 2025. Revenue was $129.3M. The company reprioritized development in Kv7 epilepsy, immune degraders, and myostatin therapies. Key trials and licensing deals are ongoing.
How this was made
The 30-second read
Why it matters
The loss and EPS miss suggest near‑term price weakness, but the pipeline progress may sustain longer‑term interest.
Market read
Primary earnings disclosure for a US‑listed biotech; new loss figures likely trigger short‑term sell‑off.
What to watch
Upcoming trial readouts for BHV‑1300 and BHV‑1400 could offset short‑term pain.
Background
Biohaven's 10‑Q provides the first public disclosure of its Q4 2026 financial results and pipeline updates.
Ticker impact
Biohaven Ltd. filed its 10‑Q reporting a $129.3M comprehensive loss and $0.86 loss per share for Q4 2026, new financial data not previously public.
downward pressure as investors price in the larger-than‑expected loss
Quarterly loss figures are fresh and materially worse than prior periods, a typical catalyst for short‑term sell‑off in biotech stocks.
Market effects
May weigh on other neuro‑degeneration and rare‑disease biotech peers.
Limited to US‑listed biotech investors.
Minimal global impact beyond sector.
Counterpoint
If the loss reflects strategic investment in pipeline assets, long‑term upside could remain.
Key entities
- companyBiohaven Ltd.
Biopharma focused on neurology and rare diseases.
